Biomarkers of aggressive pituitary adenomas

Journal of Molecular Endocrinology

Volumn 49, Issue 2, 2012, Pages

  Mete, Ozgur ^a,b,c   Ezzat, Shereen ^a,b,c   Asa, Sylvia L ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4; GELATINASE A; GROWTH HORMONE RECEPTOR; INTERSTITIAL COLLAGENASE; KI 67 ANTIGEN; MATRILYSIN; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; MICRORNA; PROTEIN P53; SECURIN; TUMOR MARKER;

CARCINOGENESIS; CHROMOSOME 11; CHROMOSOME 11Q; CHROMOSOME DELETION; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE TYPING;

ADENOMA; CARRIER PROTEINS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; GENES, P53; HUMANS; KI-67 ANTIGEN; MATRIX METALLOPROTEINASES; MICRORNAS; MUTATION; NEOPLASM PROTEINS; PITUITARY NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; TUMOR MARKERS, BIOLOGICAL;

EID: 84866389505     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-12-0113     Document Type: Review

References (120)

1. Abbass SA, Asa SL & Ezzat S 1997 Altered expression of fibroblast growth factor receptors in human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 82 1160-1166. (doi:10.1210/jc.82.4.1160)
2. Ahmed NU, Ueda M, Ito A, Ohashi A, Funasaka Y & Ichihashi M 1997 Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma. Melanoma Research 7 299-305. (doi:10.1097/00008390-199708000-00004)
3. Al-Shraim M & Asa SL 2006 The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathologica 111 1-7. (doi:10.1007/s00401-005-1093-6)
4. Altaş M, Bayrak OF, Ayan E, Bolukbasi F, Silav G, Coskun KK, Culha M, Sahin F, Sevli S & Elmaci I 2010 The effect of polymorphisms in the promoter region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma. Acta Neurochirurgica 152 1611-1617. (doi:10.1007/s00701-010-0671-0)
5. Amaral FC, Torres N, Saggioro F, Neder L, Machado HR, Silva WA Jr, Moreira AC & Castro M 2009 MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. Journal of Clinical Endocrinology and Metabolism 94 320-323. (doi:10.1210/jc.2008-1451)
6. Arakaki PA, Marques MR & Santos MC 2009 MMP-1 polymorphism and its relationship to pathological processes. Journal of Biosciences 34 313-320. (doi:10.1007/s12038-009-0035-1)
7. Asa SL 1991 The role of hypothalamic hormones in the pathogenesis of pituitary adenomas. Pathology, Research and Practice 187 581-583. (doi:10.1016/S0344-0338(11)80149-4)
8. Asa SL 2011 Tumors of the pituitary gland. Fascicle 15, 4th Series. In The Atlas of Tumor Pathology. Washington DC: Armed Forces Institute of Pathology.
9. Asa SL & Ezzat S 2005 Genetics and proteomics of pituitary tumors. Endocrine 28 43-47. (doi:10.1385/ENDO:28:1:043)
10. Asa SL & Ezzat S 2009 The pathogenesis of pituitary tumors. Annual Review of Pathology 4 97-126. (doi:10.1146/annurev.pathol.4. 110807.092259)
11. Asa SL, Coschigano KT, Bellush L, Kopchick JJ & Ezzat S 2000 Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptordeficient mice. American Journal of Pathology 156 1009-1015. (doi:10.1016/S0002-9440(10)64968-1)
12. Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, Frank SJ & Ezzat S 2007 A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Research 67 7505-7511. (doi:10.1158/0008-5472.CAN-07-0219)
13. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I et al. 2002 Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Research 62 840-847.
14. Bates AS, Farrell WE, Bicknell JE, McNicol AM, Talbot JA, Broome JC, Perrett CW, Thakker RV & Clayton RN 1997 Genetic instability in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. Journal of Clinical Endocrinology and Metabolism 82 818-824. (doi:10.1210/jc.82.3.818)
15. Bhayana S, Booth GL, Asa SL, Kovacs K & Ezzat S 2005 The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism 90 6290-6295. (doi:10.1210/jc.2005-0998)
16. Bosman FT, Carneiro F, Hruban RH & Theise ND (eds) 2010 WHO classification of tumours of the digestive system. Lyon: IARC.
17. Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli MC & degli Uberti EC 2004 miR-15a and miR-16-1 down-regulation in pituitary adenomas. Journal of Cellular Physiology 204 280-285. (doi:10.1002/jcp.20282)
18. Buttice G, Duterque-Coquillaud M, Basuyaux JP, Carrere S, Kurkinen M & Stehelin D 1996 Erg, an Ets-family member, differentially regulates human collagenase1 (MMP-1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 13 2297-2306.
19. Cavallaro U, Niedermeyer J, Fuxa M & Christofori G 2001 N-CAM modulates tumour-cell adhesion to matrix by inducing FGFreceptor signalling. Nature Cell Biology 3 650-657. (doi:10.1038/35083041)
20. Chakraborti S, Mandal M, Das S, Mandal A & Chakraborti T 2003 Regulation of matrix metalloproteinases: an overview. Molecular and Cellular Biochemistry 253 269-285. (doi:10.1023/A:1026028303196)
21. Chen X, Song F, Dai Y, Bao X & Jin Y 2003 A novel mutation of the growth hormone receptor gene (GHR) in a Chinese girl with Laron syndrome. Journal of Pediatric Endocrinology & Metabolism 16 1183-1189. (doi:10.1515/JPEM.2003.16.8.1183)
22. Chesnokova V, Kovacs K, Castro AV, Zonis S & Melmed S 2005 Pituitary hypoplasia in PttgK/K mice is protective for RbC/K pituitary tumorigenesis. Molecular Endocrinology 19 2371-2379. (doi:10.1210/me.2005-0137)
23. Colao A, Grasso LF, Pivonello R & Lombardi G 2011 Therapy of aggressive pituitary tumors. Expert Opinion on Pharmacotherapy 12 1561-1570. (doi:10.1517/14656566.2011.568478)
24. Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prévot V, Lassalle P, Trouillas J, Delehedde M & Maurage CA 2012 Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathology. In press. (doi:10.1111/j.1750-3639.2012.00578.x)
25. da Costa Andrade VC, Parise O Jr, Hors CP, de Melo Martins PC, Silva AP & Garicochea B 2007 The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Experimental and Molecular Pathology 82 53-57. (doi:10.1016/j.yexmp.2006.05.003)
26. Daita G & Yonemasu Y 1996 Dural invasion and proliferative potential of pituitary adenomas. Neurologia Medico-Chirurgica 36 211-214. (doi:10.2176/nmc.36.211)
27. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A 2006 High prevalence of pituitary adenomas: a crosssectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 91 4769-4775. (doi:10.1210/jc. 2006-1668)
28. Daniel L, Trouillas J, Renaud W, Chevallier P, Gouvernet J, Rougon G & Figarella-Branger D 2000 Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor inWistar-Furth rats) is related to growth rate and malignancy. Cancer Research 60 80-85.
29. DeLellis RA, Lloyd RV, Heitz PU & Eng C, eds 2004 World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press.
30. De Moerlooze L, Spencer-Dene B, Revest J, Hajihosseini M, Rosewell I & Dickson C 2000 An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 127 483-492.
31. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG & Kovacs K 1995a In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. European Journal of Endocrinology 133 686-690. (doi:10.1530/eje.0. 1330686)
32. Ezzat S, Smyth HS, Ramyar L & Asa SL 1995b Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 80 878-884. (doi:10.1210/jc.80.3.878)
33. Ezzat S, Zheng L, Zhu XF, Wu GE & Asa SL 2002 Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation 109 69-78.
34. Ezzat S, Yu S & Asa SL 2003 Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 50 fibroblast growth factor receptor-4 promoter. American Journal of Pathology 163 1177-1184. (doi:10.1016/S0002-9440(10)63477-3)
35. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML & McCutcheon IE 2004a The prevalence of pituitary adenomas: a systematic review. Cancer 101 613-619. (doi:10.1002/cncr.20412)
36. Ezzat S, Zheng L & Asa SL 2004b Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Molecular Endocrinology 18 2543-2552. (doi:10.1210/me.2004-0182)
37. Ezzat S, Zheng L, Winer D & Asa SL 2006 Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. Molecular Endocrinology 20 2965-2975. (doi:10.1210/me.2006-0223)
38. Fernandez A, Karavitaki N & Wass JA 2010 Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology 72 377-382. (doi:10.1111/j.1365-2265.2009.03667.x)
39. Ferrara N, Schweigerer L, Neufeld G, Mitchell R & Gospodarowicz D 1987 Pituitary follicular cells produce basic fibroblast growth factor. PNAS 84 5773-5777. (doi:10.1073/pnas.84.16.5773)
40. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G & Chanson P 2006 Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology 65 536-543. (doi:10.1111/j.1365-2265.2006.02630.x)
41. Frullanti E, Berking C, Harbeck N, Jézéquel P, Haugen A, Mawrin C, Parise O Jr, Sasaki H, Tsuchiya N & Dragani TA 2011 Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. European Journal of Cancer Prevention 20 340-347. (doi:10.1097/CEJ.0b013e3283457274)
42. Giri D, Ropiquet F & IttmannM1999 Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clinical Cancer Research 5 1063-1071.
43. Givol D & Yayon A 1992 Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB Journal 6 3362-3369.
44. Gong J, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Lopes MB, Hussaini IM & Laws ER 2008 Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary 11 37-48. (doi:10.1007/s11102-007-0066-2)
45. González-Arriaga P, PascualT, García-Alvarez A, Fernández-Somoano A, López-CimaMF&Tardón A 2012 Genetic polymorphisms inMMP2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer 12 121. (doi:10.1186/1471-2407-12-121)
46. Gospodarowicz D, Ferrara N, Schweigerer L & Neufeld G 1987 Structural characterization and biological functions of fibroblast growth factor. Endocrine Reviews 8 95-114. (doi:10.1210/edrv-8-2-95)
47. Henriksson ML, Edin S, Dahlin AM, Oldenborg PA, Öberg Å, Van Guelpen B, Rutegård J, Stenling R & Palmqvist R 2011 Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. American Journal of Pathology 178 1387-1394. (doi:10.1016/j.ajpath.2010.12.008)
48. Hentschel SJ, McCutcheon E, Moore W & Durity FA 2003 p53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Canadian Journal of Neurological Sciences 30 215-219.
49. Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP & Burrin JM 2003 The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. European Journal of Endocrinology 148 203-211. (doi:10.1530/eje.0.1480203)
50. Hussaini IM, Trotter C, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Agi CU, Redpath GT, Fang Z, Leung GK et al. 2007 Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. American Journal of Pathology 170 356-365. (doi:10.2353/ajpath.2007. 060736)
51. Ishikawa H, Heaney AP, Yu R, Horwitz GA & Melmed S 2001 Human pituitary tumor-transforming gene induces angiogenesis. Journal of Clinical Endocrinology andMetabolism 86 867-874. (doi:10.1210/jc.86. 2.867)
52. Iuchi S, Saeki N, Uchino Y, Higuchi Y, Tatsuno I, Nakamura S, Yasuda T & Yamaura A 2000 Cavernous sinus invasion and tumor proliferative potential of growth hormone-producing pituitary tumors. Endocrine Journal 47 (Suppl) S77-S79. (doi:10.1507/endocrj.47. SupplMarch_S77)
53. Jaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, Pyrhonen S, Lehtovirta P & Nevanlinna H 1993 Amplification of fgfr4 gene in human breast and gynecological cancers. International Journal of Cancer 54 378-382. (doi:10.1002/ijc.2910540305)
54. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A & Cantore G 2002 A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocrine-Related Cancer 9 103-113. (doi:10.1677/erc.0.0090103)
55. Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K & Kurisu K 1996 Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochirurgica 138 1442-1448. (doi:10.1007/BF01411124)
56. Kiechle-Schwarz M, Bauknecht T, Wienker T, Walz L & Pfleiderer A 1993 Loss of constitutional heterozygosity on chromosome 11p in human ovarian cancer. Positive correlation with grade of differentiation. Cancer 72 2423-2432. (doi:10.1002/1097-0142(19931015)72:8!2423::AID-CNCR2820720821O3.0.CO;2-P)
57. Kitamura Y, Shimizu K, Tanaka S, Ito K & Emi M 2000 Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes, Chromosomes&Cancer 27 244-251. (doi:10.1002/(SICI)1098-2264(200003)27:3!244::AID-GCC4O3.0.CO;2-7)
58. Landolt AM, Shibata T & Kleihues P 1987 Growth rate of human pituitary adenomas. Journal of Neurosurgery 67 803-806. (doi:10.3171/jns.1987.67.6.0803)
59. Lath R, Chacko G & Chandy MJ 2001 Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody. Neurology India 49 144-147.
60. LiuW, Matsumoto Y, OkadaM, MiyakeK, Kunishio K, KawaiN, TamiyaT & Nagao S 2005 Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. Journal of Medical Investigation 52 151-158. (doi:10.2152/jmi.52.151)
61. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA & Gittoes NJ 2002 Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 87 4238-4244. (doi:10.1210/jc.2002-020309)
62. Mete O & Asa SL 2012 Clinicopathological correlations in pituitary adenomas. Brain Pathology 22 443-453. (doi:10.1111/j.1750-3639. 2012.00599.x)
63. Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, Koga Y &Miyazaki K 2004 Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. British Journal of Cancer 90 1265-1273. (doi:10.1038/sj.bjc.6601685)
64. Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, Shimizu K & Inoue H 2003 Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98 2245-2250. (doi:10.1002/cncr.11778)
65. Morita K, Takano K, Yasufuku-Takano J, Yamada S, Teramoto A, Takei M, Osamura RY, Sano T & Fujita T 2008 Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein a subunit (gsp) mutation in human GH-secreting pituitary adenomas. Clinical Endocrinology 68 435-441. (doi:10.1111/j.1365-2265.2007.03062.x)
66. Morrison RS, Yamaguchi F, Bruner JM, Tang M, McKeehan W & Berger MS 1994 Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Research 54 2794-2799.
67. Nasr HB, Mestiri S, Chahed K, Bouaouina N, Gabbouj S, Jalbout M & Chouchane L 2007 Matrix metalloproteinase-1 (K1607) 1G/2G and-9 (K1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas. Clinica Chimica Acta 384 57-63. (doi:10.1016/j.cca.2007.05.018)
68. Newey PJ & Thakker RV 2011 Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. Endocrine Practice 17 (Suppl 3) 8-17. (doi:10.4158/EP10379.RA)
69. Nishizawa R, Nagata M, Noman AA, Kitamura N, Fujita H, Hoshina H, Kubota T, Itagaki M, Shingaki S, Ohnishi M et al. 2007 The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer 7 187. (doi:10.1186/1471-2407-7-187)
70. Ohta T, Yamamoto M, Numata M, Iseki S, Tsukioka Y, Miyashita T, Kayahara M, Nagakawa T, Miyazaki I, Nishikawa K et al. 1995 Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. British Journal of Cancer 72 824-831. (doi:10.1038/bjc.1995.420)
71. Ota I, Li XY, Hu Y & Weiss SJ 2009 Induction of a MT1-MMP and MT2-MMP dependent basement membrane transmigration program in cancer cells by Snail1. PNAS 106 20318-20323. (doi:10.1073/pnas. 0910962106)
72. Ozer E, Canda MS, Ulukus C, Guray M & Erbayraktar S 2003 Expression of Bcl-2, Bax and p53 proteins in pituitary adenomas: an immunohistochemical study. Tumori 89 54-59.
73. Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA & Stratakis CA 2000 Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). Journal of Clinical Endocrinology and Metabolism 85 3860-3865. (doi:10.1210/jc.85.10.3860)
74. Pack SD, Qin LX, Pak E, Wang Y, Ault DO, Mannan P, Jaikumar S, Stratakis CA, Oldfield EH, Zhuang Z et al. 2005 Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization. Genes, Chromosomes&Cancer 43 72-82. (doi:10.1002/gcc.20162)
75. Paek KI, Kim SH, Song SH, Choi SW, Koh HS, Youm JY & Kim Y 2005 Clinical significance of Ki-67 labeling index in pituitary macroadenoma. Journal of Korean Medical Science 20 489-494. (doi:10.3346/jkms.2005.20.3.489)
76. Paez-Pereda M, Kuchenbauer F, Arzt E & Stalla GK 2005 Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix. Brazilian Journal of Medical and Biological Research 38 1487-1494. (doi:10.1590/S0100-879X2005001000005)
77. Page-McCaw A, Ewald AJ & Werb Z 2007 Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews. Molecular Cell Biology 8 221-233. (doi:10.1038/nrm2125)
78. Pan LX, Chen ZP, Liu YS & Zhao JH 2005 Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. Journal of Neuro-Oncology 74 71-76. (doi:10.1007/s11060-004-6150-9)
79. Pei L & Melmed S 1997 Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 11 433-441. (doi:10.1210/me.11.4.433)
80. Pizarro CB, Oliveira MC, Coutinho LB & Ferreira NP 2004 Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Brazilian Journal of Medical and Biological Research 37 235-243. (doi:10.1590/S0100-879X2004000200011)
81. Putzolu M, Meloni A, Loche S, Pischedda C, Cao A & Moi P 1997 A homozygous nonsense mutation of the human growth hormone receptor gene in a Sardinian boy with Laron-type dwarfism. Journal of Endocrinological Investigation 20 286-288.
82. Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li CC, Hirokawa M, Kovacs K & Ezzat S 2004 Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. Journal of Clinical Endocrinology and Metabolism 89 1904-1911. (doi:10.1210/jc.2003-031489)
83. Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S, Wang EL, Rahman MM, Inoue H, Itakura M et al. 2009 Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Modern Pathology 22 431-441. (doi:10.1038/modpathol. 2008.202)
84. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E et al. 2010 Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. Journal of Clinical Endocrinology and Metabolism 95 1708-1716. (doi:10.1210/jc.2009-1191)
85. Rowe RG & Weiss SJ 2009 Navigating ECM barriers at the invasive front: the cancer cell-stroma interface. Annual Review of Cell and Developmental Biology 25 567-595. (doi:10.1146/annurev.cellbio.24. 110707.175315)
86. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ & Brinckerhoff CE 1998 A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Research 58 5321-5325.
87. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV & Cusimano M 2008 Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocrine-Related Cancer 15 721-743. (doi:10.1677/ERC-08-0012)
88. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV & Cusimano M 2009 Ki-67 in pituitary neoplasms: a review-part I. Neurosurgery 65 429-437. (doi:10.1227/01.NEU.0000349930.66434.82)
89. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV & Cusimano M 2010 Biomarkers of pituitary neoplasms: a review (Part II). Neurosurgery 67 1790-1798. (doi:10.1227/NEU.0b013e3181faa680)
90. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T et al. 2006 Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59 341-353 (discussion 341-353). (doi:10.1227/01.NEU. 0000223437.51435.6E)
91. Sharrocks AD, Brown AL, Ling Y & Yates PR 1997 The ETS domain transcription factor family. International Journal of Biochemistry&Cell Biology 29 1371-1387. (doi:10.1016/S1357-2725(97)00086-1)
92. Shevah O, Galli-Tsinopoulou A, Rubinstein M, Nousia-Arvanitakis S & Laron Z 2004 Classical Laron syndrome in a girl with a heterozygous mutation and heterozygous polymorphism of the growth hormone receptor gene. Journal of Pediatric Endocrinology & Metabolism 17 371-374. (doi:10.1515/JPEM.2004.17.3.371)
93. Shimizu Y, Kondo S, Shirai A, Furukawa M & Yoshizaki T 2008 A single nucleotide polymorphism in the matrix metalloproteinase-1 and interleukin-gene promoter predicts poor prognosis in tongue cancer. Auris, Nasus, Larynx 35 381-389. (doi:10.1016/j.anl.2007. 12.002)
94. Shin EY, Lee BH, Yang JH, Shin KS, Lee GK, Yun HY, Song YJ, Park SC & Kim EG 2000 Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. Journal of Cancer Research and Clinical Oncology 126 519-528. (doi:10.1007/s004320000128)
95. Sivapragasam M, Rotondo F, Lloyd RV, Scheithauer BW, Cusimano M, Syro LV & Kovacs K 2011 MicroRNAs in the human pituitary. Endocrine Pathology 22 134-143. (doi:10.1007/s12022-011-9167-6)
96. Stilling G, Sun Z, Zhang S, Jin L, Righi A, Kovacs G, Korbonits M, Scheithauer BW, Kovacs K & Lloyd RV 2010 MicroRNA expression in ACTH-producing pituitary tumors: upregulation of micro-RNA-122 and-493 in pituitary carcinomas. Endocrine 38 67-75. (doi:10.1007/s12020-010-9346-0)
97. Sugiyama N, Varjosalo M, Meller P, Lohi J, Chan KM, Zhou Z, Alitalo K, Taipale J, Keski-Oja J & Lehti K 2010 FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of amembrane type 1 matrix metalloproteinase-FGFR4 complex. PNAS 107 15786-15791. (doi:10.1073/pnas.0914459107)
98. Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R & Jones TH 2001 Mdm2 and the p53 pathway in human pituitary adenomas. Clinical Endocrinology 54 317-325. (doi:10.1046/j.1365-2265.2001.01195.x)
99. Tahir A, Chahal HS & Korbonits M 2010 Molecular genetics of the aip gene in familial pituitary tumorigenesis. Progress in Brain Research 182 229-253.
100. Tateno T, Asa SL, Zheng L, Mayr T, Ullrich A & Ezzat S 2011 The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. PLoS Genetics 7 e1002400. (doi:10.1371/journal. pgen.1002400)
101. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D & Laws ER Jr 1996a Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38 99-106 (discussion 106-7). (doi:10.1097/00006123-199601000-00024)
102. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ & Laws ER Jr 1996b p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38 765-770. (doi:10.1227/00006123-199604000-00027)
103. Voorter CE, Ummelen MI, Ramaekers FS & Hopman AH 1996 Loss of chromosome 11 and 11 p/q imbalances in bladder cancer detected by fluorescence in situ hybridization. International Journal of Cancer 65 301-307. (doi:10.1002/(SICI)1097-0215(19960126)65:3! 301::AID-IJC4O3.0.CO;2-3)
104. Wang F, Shu K, Lei T & Xue D 2008 The expression of integrin-b1 and FAK in pituitary adenomas and their correlation with invasiveness. Journal of Huazhong University of Science and Technology. Medical Sciences 28 572-575. (doi:10.1007/s11596-008-0518-6)
105. Wasylyk C, Gutman A, Nicholson R & Wasylyk B 1991 The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO Journal 10 1127-1134.
106. Weil RJ, Vortmeyer AO, Huang S, Boni R, Lubensky IA, Pack S, Marx SJ, Zhuang Z & Oldfield EH 1998 11q13 allelic loss in pituitary tumors in patients with multiple endocrine neoplasia syndrome type 1. Clinical Cancer Research 4 1673-1678.
107. Westermarck J, Seth A & Kahari VM 1997 Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 14 2651-2660. (doi:10.1038/sj.onc. 1201111)
108. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fèvre-Montange M, Rey C, Figarella-Branger D et al. 2007 A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocrine-Related Cancer 14 887-900. (doi:10.1677/ERC-07-0062)
109. WierinckxA, Roche M, Raverot G, Legras-LachuerC, Croze S, NazaretN, Rey C, Auger C, Jouanneau E, Chanson P et al. 2011 Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathology 21 533-543.
110. Wolfsberger S, Wunderer J, Zachenhofer I, CzechT, Böcher-SchwarzHG, Hainfellner J & Knosp E 2004 Expression of cell proliferation markers in pituitary adenomas-correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIa. Acta Neurochirurgica 146 831-839.
111. Woo M, Park K, Nam J & Kim JC 2007 Clinical implications of matrix metalloproteinase-1,-3,-7,-9,-12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. Journal of Gastroenterology and Hepatology 22 1064-1070. (doi:10.1111/j.1440-1746.2006.04424.x)
112. Yamada SM, Yamada S, Hayashi Y, Takahashi H, Teramoto A & Matsumoto K 2002 Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. Neurological Research 24 244-248. (doi:10.1179/016164102101199864)
113. Yonezawa K, Tamaki N & Kokunai T 1997 Clinical features and growth fractions of pituitary adenomas. Surgical Neurology 48 494-500. (doi:10.1016/S0090-3019(97)00102-X)
114. YoshimuraN, SanoH, Hashiramoto A, Yamada R, NakajimaH, KondoM & Oka T 1998 The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clinical Immunology and Immunopathology 89 28-34. (doi:10.1006/clin.1998.4551)
115. Yu S, Asa SL & Ezzat S 2002 Fibroblast growth factor receptor 4 is a target for the zinc-finger transcription factor Ikaros in the pituitary. Molecular Endocrinology 16 1069-1078. (doi:10.1210/me.16.5.1069)
116. Yu S, Asa SL, Weigel RJ & Ezzat S 2003 Pituitary tumor AP-2a recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. Journal of Biological Chemistry 278 19597-19602. (doi:10.1074/jbc.M212432200)
117. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD & Melmed S 1999 Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84 761-767. (doi:10.1210/jc.84.2.761)
118. Zhao D, Tomono Y & Nose T 1999 Expression of P27kip1 and Ki-67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochirurgica 141 187-192. (doi:10.1007/s007010050285)
119. Zhu X, Asa SL & Ezzat S 2008 Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clinical Cancer Research 14 1984-1996. (doi:10.1158/1078-0432.CCR-07-2003)
120. Zou H, McGarry TJ, Bernal T & Kirschner MW 1999 Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285 418-422. (doi:10.1126/science.285.5426.418)